Type 2 diabetes: an expanded view of pathophysiology and therapy (Q37750278)

22 August 2017

1 reference

title

Type 2 diabetes: an expanded view of pathophysiology and therapy (English)

1 reference

22 August 2017

0 references

1 reference

Jeff Unger

1

1 reference

PubMed ID

20463424

22 August 2017

Christopher G Parkin

series ordinal

2

1 reference

PubMed ID

20463424

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

22 August 2017

Postgraduate Medicine

1 reference

22 August 2017

122

1 reference

22 August 2017

3

1 reference

22 August 2017

145-157

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

22 August 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Glucose Metabolism and Regulation: Beyond Insulin and Glucagon

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Impaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Effect of Age and Diet on Insulin Secretion and Insulin Action in the Rat

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Glucose intolerance and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Free fatty acids, insulin resistance, and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Lack of a gastrointestinal mediator of insulin action in maturity-onset diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Standards of medical care in diabetes--2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Psychosocial aspects of diabetes with an emphasis on depression

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

The prevalence of comorbid depression in adults with diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the Ameri

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

American College of Sports Medicine position stand. Exercise and type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Diabetes Self-Management Education Core Outcomes Measures

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Value of self-monitoring blood glucose pattern analysis in improving diabetes outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Metformin: new understandings, new uses

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Obesity: new perspectives and pharmacotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Metabolic consequences of hyperglycemia and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Insulin-sensitizing agents--thiazolidinediones (glitazones).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Comparative safety of newer oral antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Increased glucose levels are associated with episodic memory in nondiabetic women

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Impairment of myocardial protection in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2152

21 January 2018

Identifiers

DOI

10.3810/PGM.2010.05.2152

1 reference

22 August 2017

1 reference

PubMed ID

20463424